(0.34%) 5 117.27 points
(0.31%) 38 359 points
(0.38%) 15 989 points
(-0.85%) $83.14
(5.82%) $2.04
(0.43%) $2 357.40
(0.48%) $27.67
(3.93%) $958.35
(-0.22%) $0.933
(-0.39%) $10.98
(-0.55%) $0.796
(1.66%) $93.40
2 days till quarter result
(bmo 2024-05-01)
Expected move: +/- 12.46%
@ $2.37
発行日: 15 2月 2024 @ 04:56
リターン: 58.35%
前回のシグナル: 2月 15 - 04:02
前回のシグナル:
リターン: -2.07 %
Live Chart Being Loaded With Signals
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer...
Stats | |
---|---|
本日の出来高 | 430 501 |
平均出来高 | 1.24M |
時価総額 | 195.49M |
EPS | $0 ( 2024-02-28 ) |
次の収益日 | ( $-0.190 ) 2024-05-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.03 |
ATR14 | $0.00600 (0.16%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-20 | Thomas Monica R. | Buy | 37 500 | Common Stock |
2024-03-20 | Avagliano Mark | Buy | 100 000 | Common Stock |
2024-03-20 | Umstead John W. V | Buy | 37 500 | Common Stock |
2024-03-18 | Umstead John W. V | Sell | 6 547 | Common Stock |
2024-02-12 | Malik Rajesh | Buy | 28 600 | Common Stock |
INSIDER POWER |
---|
72.69 |
Last 100 transactions |
Buy: 2 421 369 | Sell: 357 781 |
ボリューム 相関
G1 Therapeutics Inc 相関
10 最も負の相関 | |
---|---|
OBT | -0.87 |
NKSH | -0.867 |
PAYA | -0.863 |
SMCI | -0.863 |
BOCH | -0.854 |
STAY | -0.851 |
LSTR | -0.848 |
ARDX | -0.846 |
PDFS | -0.844 |
AVGO | -0.84 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
G1 Therapeutics Inc 相関 - 通貨/商品
G1 Therapeutics Inc 財務諸表
Annual | 2023 |
収益: | $82.51M |
総利益: | $75.32M (91.28 %) |
EPS: | $-0.930 |
FY | 2023 |
収益: | $82.51M |
総利益: | $75.32M (91.28 %) |
EPS: | $-0.930 |
FY | 2022 |
収益: | $51.30M |
総利益: | $47.55M (92.69 %) |
EPS: | $-3.38 |
FY | 2021 |
収益: | $31.48M |
総利益: | $29.46M (93.60 %) |
EPS: | $-3.50 |
Financial Reports:
No articles found.
G1 Therapeutics Inc
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer; Phase III clinical trial for the treatment of first line triple negative breast cancer; Phase II clinical trial for patients with first line bladder cancer; Phase II clinical trial for patients with combination with the antibody-drug conjugate; and Phase II clinical trial for the treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。